Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalNeurologyNeurodevelopmental DisordersTrial Update

Study on MRI Findings and Executive Functions in Preterm Infants

This study is critical as it explores the correlation between MRI findings and executive functions in preterm infants, which could inform future therapeutic strategies. Insights gained may lead to targeted interventions that enhance neurodevelopmental outcomes, impacting product development in pediatric neurology.

Published: June 21, 2026
Updated: June 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Neurodevelopmental Disorders
Asset: Study
Trial SummaryCLN

Phase III

Neurology / Neurodevelopmental Disorders

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This study is critical as it explores the correlation between MRI findings and executive functions in preterm infants, which could inform future therapeutic strategies. Insights gained may lead to targeted interventions that enhance neurodevelopmental outcomes, impacting product development in pediatric neurology.

Why it matters

This study is critical as it explores the correlation between MRI findings and executive functions in preterm infants, which could inform future therapeutic strategies. Insights gained may lead to targeted interventions that enhance neurodevelopmental outcomes, impacting product development in pediatric neurology.

What changed

Trial Update

Analysis

This study aims to correlate MRI findings at term age in preterm infants with their executive functions and neurodevelopmental outcomes.

This study is critical as it explores the correlation between MRI findings and executive functions in preterm infants, which could inform future therapeutic strategies. Insights gained may lead to targeted interventions that enhance neurodevelopmental outcomes, impacting product development in pediatric neurology.

Monitor results from this study for insights into the relationship between MRI findings and cognitive outcomes in preterm infants.

Related companies & assets

Assets

  • Study →
  • preterm infant therapies →

Sources & Humanexa intelligence

Source links

  • Study on MRI Findings and Executive Functions in Preterm Infants ↗

Related Humanexa pages

  • Study on MRI Findings and Executive Functions in Preterm Infants →

Related signals

Trial SummaryCLN

Phase III

gastric cancer therapies

Status

Active

Signal Score

8.4

Clinicalhigh signal

FTO/BCL6 Axis Identified as Therapeutic Target in Gastric Cancer Progression

FTO-mediated demethylation of BCL6 promotes gastric cancer progression by inhibiting ferroptosis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

epithelial ovarian cancer

Status

Active

Signal Score

8.4

Clinicalhigh signal

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Hesperidin-loaded PEGylated PLGA nanoparticles demonstrate improved dissolution and cytotoxicity in EOC models.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.